Results 41 to 50 of about 666,379 (164)

Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic

Türk Kardiyoloji Derneği Arşivi, 2014
Objectives: Familial hypercholesterolemia (FH) is a genetic disease characterized by extremely high levels of cholesterol leading to premature atherosclerosis. In homozygous individuals (HoFH) cardiovascular events could develop in child-hood.
Meral Kayıkçıoğlu, Erkan Kısmalı, Levent Can, Serdar Payzin   +3 more
doaj   +1 more source

Facilitators, barriers, and insights using an HFA‐PEFF‐based clinical decision support system: A proof‐of‐concept study

ESC Heart Failure, Volume 12, Issue 5, Page 3655-3666, October 2025.
Analysis of the usage of the HFA‐PEFF score‐based clinical decision support system (CDSS) and the main barriers and facilitators to its implementation, based on a survey of physicians. Abstract Background and aims Knowing that heart failure (HF) with preserved ejection fraction (HFpEF) can be difficult to diagnose, a clinical decision support system ...
Isidora Milosavljević, Ivan Petrović, Aleksandra Ilić, Dragana Dabović, Aleksandra Milovančev, Goran Remer, Vladimir Vuković, Dimitrije Zdravković, Maja Stefanović, Snežana Stojšić, Ana Balenović, Goran Lončar, Snežana Tadić, Milana Jaraković, Snežana Bjelić, Snežana Čemerlić, Marija Bjelobrk, Tatjana Miljković, Andrej Preveden, Milovan Petrović, Srdjan Maletin, Tanja Popov, Vanja Drljević Todić, Mirko Todić, Aleksandra Vulin, Milenko Čanković, Dragica Andrić, Dragoslava Živkov Šaponja, Aleksandar Redžek, Anastazija Stojšić Milosavljević   +29 more
wiley   +1 more source

Clinical, Anthropometric and Biochemical Characteristics of Patients with or without Genetically Confirmed Familial Hypercholesterolemia

Arquivos Brasileiros de Cardiologia
Background: Familial hypercholesterolemia (FH) is a common autosomal dominant disorder, characterized by a high level of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature cardiovascular disease. Objective: To evaluate clinical and
Andrea De Lorenzo, Juliana Duarte Lopes da Silva, Cinthia E. James, Alexandre C. Pereira, Annie Seixas Bello Moreira   +4 more
doaj   +1 more source

Protective mechanisms against Alzheimer's disease in APOE3‐Christchurch homozygous astrocytes

Alzheimer's &Dementia, Volume 21, Issue 9, September 2025.
Abstract INTRODUCTION Alzheimer's disease (AD) is characterized by tau pathology, leading to neurodegeneration. Astrocytes regulate central nervous system homeostasis and influence AD progression. The APOE3‐Christchurch (APOE3‐Ch) variant is linked to AD resilience, but its protective mechanisms remain unclear.
Xinran Tian, Erica Keane Rivera, Inyoung Hwang, Arina A. Nikitina, Jennifer A. Smith, Youngsuh J. Cho, Julia Sala‐Jarque, Austin DuBose, Clare Andriola, Toby Gollan‐Myers, Kenneth S. Kosik   +10 more
wiley   +1 more source

Incorporating familial risk, lifestyle factors, and pharmacogenomic insights into personalized noncommunicable disease (NCD) reports for healthcare funder beneficiaries participating in the Open Genome Project

Annals of Human Genetics, Volume 89, Issue 4, Page 208-227, July 2025.
Abstract Introduction An ethics‐guided decision‐making framework was developed for applying pathology‐supported genetic testing, a multifaceted pharmacodiagnostic approach that translates population risk stratification into clinical utility. We introduce this service, supported by the Open Genome Project, which aligns with the beneficence principle in ...
Manie De Klerk, Nicole Van Der Merwe, Johny Erasmus, Lindiwe Whati, Kelebogile E. Moremi, Daniel W. Olivier, Maritha J. Kotze   +6 more
wiley   +1 more source

Clinical features, biomarker profiles, and neuroimaging characteristics in patients from memory clinic in china: The Shanghai Memory Study

Alzheimer's &Dementia, Volume 21, Issue 6, June 2025.
Abstract INTRODUCTION Despite advances in biomarker assessment, molecular neuroimaging, and disease‐modifying therapies for cognitive disorders, China lacks well‐characterized clinical cohorts integrating comprehensive clinical assessments and multimodal biomarkers.
Jie Wang, Xiaoxi Ma, Jiaying Lu, Jie Wu, Zhenxu Xiao, Huiwei Zhang, Weiqi Bao, Saineng Ding, Li Zheng, Xiaoniu Liang, Yihui Guan, Chuantao Zuo, Ding Ding, Qianhua Zhao, the Shanghai Memory Study (SMS)   +14 more
wiley   +1 more source

Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery Disease

Clinical Transplantation, Volume 39, Issue 6, June 2025.
ABSTRACT Background: Cardiac allograft vasculopathy (CAV) remains a barrier to long‐term survival after heart transplantation. Little is known about cardiovascular biomarkers in CAV and how they compare to biomarkers in atherosclerotic coronary artery disease (CAD).
Lukas Köster, Jessica Weimann, Alexander Bernhard, Benjamin Bay, Christopher M. Blaum, Thiess Lorenz, Tanja Zeller, Christoph Waldeyer, Hermann Reichenspurner, Paulus Kirchhof, Stefan Blankenberg, Christina Magnussen, Fabian J. Brunner   +12 more
wiley   +1 more source

Human macrophage pro‐inflammatory polarization in response to free cholesterol and cholesterol remnants

Physiological Reports, Volume 13, Issue 10, May 2025.
Abstract Atherosclerosis is a chronic inflammatory disease of the blood vessels caused by elevated levels of lipoproteins. The hyperlipoproteinemia triggers a series of cellular changes, particularly the activation of the macrophages, which play a crucial role in the development and progression of atherosclerosis.
Karel Paukner, Barbora Muffova, Hana Bartuskova, Jan Mareš, Libor Janousek, Jiri Fronek, Sona Kauerova, Ivana Kralova Lesna, Rudolf Poledne   +8 more
wiley   +1 more source

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease

Journal of Clinical Apheresis, Volume 40, Issue 2, April 2025.
ABSTRACT Elevated Lipoprotein(a) (Lp(a)) is a known independent cardiovascular risk factor. Lp(a) Lipoprotein Apheresis (LA) substantially reduces the number of cardiovascular events. The effect of LA treatment in hemodialysis (HD) patients remains unknown. Retrospective analysis of nine patients undergoing LA and HD.
Tilmann Röseler, Daniel Kayser, Georg Schlieper, Wanja M. Bernhardt   +3 more
wiley   +1 more source

Evaluating Red Blood Cells' Membrane Fluidity in Diabetes: Insights, Mechanisms, and Future Aspects

Diabetes/Metabolism Research and Reviews, Volume 41, Issue 1, January 2025.
ABSTRACT Aims This review evaluates the mechanisms underlying red blood cell (RBC) membrane fluidity changes in diabetes mellitus (DM) and explores strategies to assess and address these alterations. Emphasis is placed on developing a comprehensive index for membrane fluidity to improve monitoring and management in diabetic patients.
Dario Pitocco, Duaa Hatem, Alessia Riente, Michele Maria De Giulio, Alessandro Rizzi, Alessio Abeltino, Cassandra Serantoni, Linda Tartaglione, Emanuele Rizzo, Lorenzo Lucacchini Paoli, Marco De Spirito, Giuseppe Maulucci   +11 more
wiley   +1 more source